First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Subscribe To Our Newsletter & Stay Updated
